Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 6/20 | 0.38 |
| ▸ | LMNA | P02545 | 3/20 | 0.38 |
| ▸ | SLC27A1 | Q6PCB7 | 4/20 | 0.37 |
| ▸ | THRB | P10828 | 1/20 | 0.36 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | NPY5R | Q15761 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3167129 | 0.83 | ALDH1A1 (0.55) | HRH3LMNAALDH1A1MAPT | |
| SCHEMBL3172485 | 0.81 | LMNA (0.43) | LMNATHRBALDH1A1MAPT | |
| SCHEMBL4801764 | 0.78 | HRH3 (0.45) | HRH3KCNH2ALDH1A1 | |
| SCHEMBL3260066 | 0.76 | HRH3 (0.44) | HRH3KCNH2ALDH1A1MAPT | |
| SCHEMBL3157384 | 0.76 | CNR1 (0.40) | LMNAALDH1A1MAPT | |
| SCHEMBL3163040 | 0.75 | HRH3 (0.43) | HRH3KCNH2 | |
| SCHEMBL3164100 | 0.75 | LMNA (0.36) | LMNASLC27A1THRBALDH1A1MAPT | |
| SCHEMBL3166113 | 0.74 | LMNA (0.53) | HRH3LMNATHRBALDH1A1MAPT | |
| SCHEMBL3164089 | 0.74 | POLB (0.47) | LMNAALDH1A1MAPT | |
| SCHEMBL3163033 | 0.73 | HRH3 (0.41) | HRH3KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1716128-B1 | SUBSTITUTED 4,5,6,7-TETRAHYDRO-BENZOTHIAZOL-2-YLAMINE COMPOUNDS | GRUENENTHAL GMBH (DE) | 2010-03-31 | — | — | EP | claimed |
| US-7348347-B2 | Substituted 4,5,6,7-tetrahydrobenzthiazol-2-ylamine compounds | GRUENENTHAL GMBH (DE) | 2008-03-25 | — | — | US | claimed |
| JP-2007522171-A | — | — | 2007-08-09 | — | — | JP | claimed |
| US-20070027315-A1 | Substituted 4,5,6,7-tetrahydrobenzthiazol-2-ylamine compounds | GRUENENTHAL GMBH (DE) | 2007-02-01 | — | — | US | claimed |
| EP-1716128-A1 | SUBSTITUTED 4,5,6,7-TETRAHYDRO-BENZOTHIAZOL-2-YLAMINE COMPOUNDS | Grünenthal GmbH (DE) | 2006-11-02 | — | — | EP | claimed |
| WO-2005077924-A1 | SUBSTITUTED 4,5,6,7-TETRAHYDRO-BENZOTHIAZOL-2-YLAMINE COMPOUNDS | Grünenthal GmbH (DE) | 2005-08-25 | — | — | WO | claimed |
| EP-1716128-B1 | SUBSTITUTED 4,5,6,7-TETRAHYDRO-BENZOTHIAZOL-2-YLAMINE COMPOUNDS | GRUENENTHAL GMBH (DE) | 2010-03-31 | — | — | EP | disclosed |
| US-7348347-B2 | Substituted 4,5,6,7-tetrahydrobenzthiazol-2-ylamine compounds | GRUENENTHAL GMBH (DE) | 2008-03-25 | — | — | US | disclosed |
| US-20070027315-A1 | Substituted 4,5,6,7-tetrahydrobenzthiazol-2-ylamine compounds | GRUENENTHAL GMBH (DE) | 2007-02-01 | — | — | US | disclosed |
| EP-1716128-A1 | SUBSTITUTED 4,5,6,7-TETRAHYDRO-BENZOTHIAZOL-2-YLAMINE COMPOUNDS | Grünenthal GmbH (DE) | 2006-11-02 | — | — | EP | disclosed |
| WO-2005077924-A1 | SUBSTITUTED 4,5,6,7-TETRAHYDRO-BENZOTHIAZOL-2-YLAMINE COMPOUNDS | Grünenthal GmbH (DE) | 2005-08-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070027315-A1 | Substituted 4,5,6,7-tetrahydrobenzthiazol-2-ylamine compounds | TPH2, HTR6, TPH1 | HRH3 970/4885LMNA 3504/4885SLC27A1 3148/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.